LOBE Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EDT
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€15.92M
Enterprise Value€13.06
Total Cash (Recent Filing)€4.96M
Total Debt (Recent Filing)€316.49K
Price to Earnings (P/E)―
Beta3.22
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,102,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
IP And R&D FocusSustained R&D and pursuit of intellectual property around novel delivery methods and compounds creates durable product differentiation. Strong IP can support licensing, exclusivity and higher margins over time if clinical and regulatory progress continues, making R&D a long-term strategic asset.
Modest LeverageLow recorded debt reduces immediate solvency pressure and preserves balance-sheet flexibility. For a cash‑burning development company, modest leverage lowers short‑term default risk and gives management scope to fund trials or partnerships without immediate debt servicing constraints.
Evidence Of Gross Profit PreviouslyHistorical gross profit when revenue existed indicates the company’s products or services can generate positive unit economics. If management can reestablish revenue streams, underlying margins suggest a path to scalable profitability rather than structurally negative product economics.
Bears Say
No Revenue And Persistent LossesThe absence of revenue and recurring operating losses reflect the business is not yet commercialized and cannot self-fund operations. Persistent negative earnings increase reliance on external capital, raise dilution risk, and reduce visibility into sustainable cash generation over the medium term.
Negative Operating And Free Cash FlowConsistent cash burn undermines runway and forces frequent financing or partnerships, which can be dilutive or costly. Negative free cash flow constrains investments in trials, commercialization, and scale-up, making long-term execution and market entry riskier without new funding.
Unstable And Sometimes Negative EquityPeriods of negative equity signal accumulated losses that have eroded shareholder capital, complicating future capital raises and increasing perceived counterparty risk. This structural weakness can make partnerships, credit access, and non‑dilutive financing harder or more expensive.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was €0.01 and its highest was €0.08 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is €15.92M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 8 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in DE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―